Recent trends in hormone therapy utilization and breast cancer incidence rates in the high incidence population of Marin County, California

Ereman, Rochelle R.; Prebil, Lee Ann; Mockus, Mary; Koblick, Kathy; Orenstein, Fern; Benz, Christopher; Clarke, Christina A.
January 2010
BMC Public Health;2010, Vol. 10 Issue 1, p228
Academic Journal
Background: Recent declines in invasive breast cancer have been reported in the US, with many studies linking these declines to reductions in the use of combination estrogen/progestin hormone therapy (EPHT). We evaluated the changing use of postmenopausal hormone therapy, mammography screening rates, and the decline in breast cancer incidence specifically for Marin County, California, a population with historically elevated breast cancer incidence rates. Methods: The Marin Women's Study (MWS) is a community-based, prospective cohort study launched in 2006 to monitor changes in breast cancer, breast density, and personal and biologic risk factors among women living in Marin County. The MWS enrolled 1,833 women following routine screening mammography between October 2006 and July 2007. Participants completed a self-administered questionnaire that included items regarding historical hormone therapy regimen (estrogen only, progesterone only, EPHT), age of first and last use, total years of use, and reason(s) for stopping, as well as information regarding complementary hormone use. Questionnaire items were analyzed for 1,083 non-Hispanic white participants ages 50 and over. Breast cancer incidence rates were assessed overall and by tumor histology and estrogen receptor (ER) status for the years 1990-2007 using data from the Northern California Surveillance, Epidemiology and End Results (SEER) cancer registry. Results: Prevalence of EPHT use among non-Hispanic white women ages 50 and over declined sharply from 21.2% in 1998 to 6.7% by 2006-07. Estrogen only use declined from 26.9% in 1998 to 22.4% by 2006-07. Invasive breast cancer incidence rates declined 33.4% between 2001 and 2004, with drops most pronounced for ER+ cancers. These rate reductions corresponded to declines of about 50 cases per year, consistent with population attributable fraction estimates for EPHT-related breast cancer. Self-reported screening mammography rates did not change during this period. Use of alternative or complementary agents did not differ significantly between ever and never hormone users. Of women who reported stopping EPHT in the past 5 years, 60% cited "health risks" or "news reports" as their primary reasons for quitting. Conclusion: A dramatic reduction in EPHT use was followed temporally by a significant reduction in invasive and ER+ breast cancer rates among women living in Marin County, California.


Related Articles

  • Issues to debate on the Women's Health Initiative study Failure of estrogen plus progestin therapy for prevention of breast cancer risk. T. Luukkainen // Human Reproduction;Aug2003, Vol. 18 Issue 8, p1559 

    Several studies on hormone replacement therapy (HRT) in the USA have been published. They revealed that the risk of breast cancer is increased with HRT more than with estrogen alone (ERT). A progestin has been given with each dose of ERT, as was the case in the Women's Health Initiative (WHI)...

  • The Potential Role of 5-Hydroxytryptophan for Hot Flash Reduction: A Hypothesis. Curcio, Jessica J.; Kim, Linda S.; Wollner, Debra; Pockaj, Barbara A. // Alternative Medicine Review;Sep2005, Vol. 10 Issue 3, p216 

    Hormone replacement therapy (HRT) is contraindicated in women with a history of breast cancer or a high risk of breast cancer development. Recent results from large clinical trials, such as the Women's Health Initiative, have demonstrated increased risks of thromboembolic events and a moderate...

  • Does sharp drop in HT use explain declining breast cancer rates?  // Contemporary OB/GYN;Nov2007, Vol. 52 Issue 11, p30 

    The article discusses the possible link of the drop in hormone therapy (HT) use to declining breast cancer rates. Anderson Cancer Center researcher Peter Ravdin explained at the 2007 North American Medical Society conference that clinical trial evidence show that combined estrogen/progestin use...

  • Medicine in the News. Pinkowish, Mary Desmond // Patient Care for the Nurse Practitioner;Aug2003, Vol. 6 Issue 8, p5 

    The article provides information on hormone therapy (HT) and breast cancer. Data from the Women's Health Initiative trial of combined estrogen plus progestin hormone therapy suggest that even short-term use of hormones increases the risk of breast-cancer. It also examines the duration between...

  • Breast cancer dropped in tandem with HT in California.  // Contemporary OB/GYN;Oct2007, Vol. 52 Issue 10, p16 

    This article discusses findings of a study that appeared in the August 10, 2007 issue of the "Journal of Clinical Oncology," which revealed the correlation between a decline in hormone therapy use in California and a drop in breast cancer rates. Counties covered by the study were divided into...

  • Estrogen plus progestin increased risk for breast cancer in postmenopausal women: COMMENTARY. Thacker, Holly L. // ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p61 

    The study by researchers R.T. Chlebowski and colleagues gives detailed information regarding breast cancer risk in late postmenopausal women using estrogen-plus-progestin hormone therapy (HT). No increased risk for breast cancer death was reported in HT users, and the diagnosis of metastatic...

  • More reports link falling breast cancer rates to change in use of hormone replacement therapy. Brown, Simon // Menopause International;Jun2009, Vol. 15 Issue 2, p48 

    This article discusses some reports associating the decrease in breast cancer rates to the reduced use of hormone replacement therapy (HRT). It remembers a report from the Women's Health Initiative in 2008 showing the association between the decrease in breast cancer rates and the reduced use of...

  • Hormone replacement therapy and benign breast disease. Hyett, Anthony R.; Sacks, Nigel P. M. // Journal of the British Menopause Society;2001, Vol. 7 Issue 1, p16 

    The exact incidence of new breast symptoms with hormone replacement therapy (HRT) and its trophic effects on benign breast disorders is not well quantified and remains relatively understudied. This is a rapidly growing clinical issue as the rate of HRT use is increasing. Significant mastalgia...

  • Hormone Therapy and Risk of Lung Cancer. Jensen, Jeffrey T. // OB/GYN Clinical Alert;Jul2010, Vol. 27 Issue 3, p20 

    The article presents a study on the role of hormone replacement therapy (HRT) in lung cancer development. Subjects of the study were peri- and postmenopausal women aged 50 to 76 years old. Data on exposure to HRT and the years of estrogen and progestin use as well as estrogen-only use were...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics